中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2015年
20期
71-73,77
,共4页
醒脾养儿颗粒%肺炎%腹泻
醒脾養兒顆粒%肺炎%腹瀉
성비양인과립%폐염%복사
Xingpi yanger granule%Pneumonia%Diarrhea
目的：醒脾养儿颗粒辅助治疗小儿肺炎继发性腹泻的临床效果及安全性观察。方法选取2010年3月~2014年9月本院收治的160例肺炎继发性腹泻患儿，将其按照随机数字表法研究组和对照组，各80例。两组患儿均给予肺炎继发性腹泻的常规治疗措施，同时对照组给予口服思密达，研究组加服醒脾养儿颗粒。治疗1个疗程后，对两组患儿治疗效果、患儿症状体征改善情况及血清胃泌素(GAS)、胃动素(MOT)、生长抑素(SS)水平进行比较。结果经治疗1个疗程后，研究组的治疗总有效率达到91.25%，显著高于对照组的80.00%，差异有统计学意义(P<0.05)；在治疗期间，研究组腹泻、发热、呕吐持续时间分别为(36.3±9.6)、(40.6±6.9)、(35.5±7.4)h，对照组分别为(48.0±11.2)、(46.1±8.2)、(42.5±11.7)h，两组差异有统计学意义(P<0.05)；与同组治疗前比较，两组患儿经治疗后的血清GAS和MOT水平明显下降，SS水平明显升高(P<0.05)；与对照组治疗后比较，研究组的GAS和MOT水平降低幅度及SS水平升高幅度更为显著，差异均有统计学意义(P<0.05)，两组患儿均未见明显药物不良反应。结论醒脾养儿颗粒辅助治疗小儿肺炎继发性腹泻的效果显著，可迅速缓解患儿腹泻症状，缩短肺炎治疗时间，同时醒脾养儿颗粒对患儿血清GAS、MOT、SS水平具有明显的调节作用，值得临床推广应用。
目的：醒脾養兒顆粒輔助治療小兒肺炎繼髮性腹瀉的臨床效果及安全性觀察。方法選取2010年3月~2014年9月本院收治的160例肺炎繼髮性腹瀉患兒，將其按照隨機數字錶法研究組和對照組，各80例。兩組患兒均給予肺炎繼髮性腹瀉的常規治療措施，同時對照組給予口服思密達，研究組加服醒脾養兒顆粒。治療1箇療程後，對兩組患兒治療效果、患兒癥狀體徵改善情況及血清胃泌素(GAS)、胃動素(MOT)、生長抑素(SS)水平進行比較。結果經治療1箇療程後，研究組的治療總有效率達到91.25%，顯著高于對照組的80.00%，差異有統計學意義(P<0.05)；在治療期間，研究組腹瀉、髮熱、嘔吐持續時間分彆為(36.3±9.6)、(40.6±6.9)、(35.5±7.4)h，對照組分彆為(48.0±11.2)、(46.1±8.2)、(42.5±11.7)h，兩組差異有統計學意義(P<0.05)；與同組治療前比較，兩組患兒經治療後的血清GAS和MOT水平明顯下降，SS水平明顯升高(P<0.05)；與對照組治療後比較，研究組的GAS和MOT水平降低幅度及SS水平升高幅度更為顯著，差異均有統計學意義(P<0.05)，兩組患兒均未見明顯藥物不良反應。結論醒脾養兒顆粒輔助治療小兒肺炎繼髮性腹瀉的效果顯著，可迅速緩解患兒腹瀉癥狀，縮短肺炎治療時間，同時醒脾養兒顆粒對患兒血清GAS、MOT、SS水平具有明顯的調節作用，值得臨床推廣應用。
목적：성비양인과립보조치료소인폐염계발성복사적림상효과급안전성관찰。방법선취2010년3월~2014년9월본원수치적160례폐염계발성복사환인，장기안조수궤수자표법연구조화대조조，각80례。량조환인균급여폐염계발성복사적상규치료조시，동시대조조급여구복사밀체，연구조가복성비양인과립。치료1개료정후，대량조환인치료효과、환인증상체정개선정황급혈청위비소(GAS)、위동소(MOT)、생장억소(SS)수평진행비교。결과경치료1개료정후，연구조적치료총유효솔체도91.25%，현저고우대조조적80.00%，차이유통계학의의(P<0.05)；재치료기간，연구조복사、발열、구토지속시간분별위(36.3±9.6)、(40.6±6.9)、(35.5±7.4)h，대조조분별위(48.0±11.2)、(46.1±8.2)、(42.5±11.7)h，량조차이유통계학의의(P<0.05)；여동조치료전비교，량조환인경치료후적혈청GAS화MOT수평명현하강，SS수평명현승고(P<0.05)；여대조조치료후비교，연구조적GAS화MOT수평강저폭도급SS수평승고폭도경위현저，차이균유통계학의의(P<0.05)，량조환인균미견명현약물불량반응。결론성비양인과립보조치료소인폐염계발성복사적효과현저，가신속완해환인복사증상，축단폐염치료시간，동시성비양인과립대환인혈청GAS、MOT、SS수평구유명현적조절작용，치득림상추엄응용。
Objective To observe the clinical effect and safety of Xingpi yanger granule as an adjuvant therapy in children with pneumonia secondary diarrhea. Methods 160 patients with pneumonia secondary diarrhea admitted into our hospital from March 2010 to September 2014 were selected and evenly divided into research group and control group by random number table.Routine treatment of secondary diarrhea of pneumonia was provided in two groups.At the same time,oral administration of smecta in the control group was added,while in research group,Xingpi yanger granule was added.After 1 course of treatment,the therapeutic effect,improvement of symptoms and signs,levels of serum gastrin (GAS),motilin(MOT)and somatostatin(SS)in the two groups was compared. Results After 1 course of treatment,the to-tal effective rate in the research group was 91.25%,which was significantly higher than 80.00% in the control group, with a statistical difference(P<0.05).During the treatment period,duration of diarrhea, fever, and vomiting in the research group was (36.3±9.6) h,(40.6±6.9) h and (35.5±7.4) h,while in the control group was (48.0±11.2) h,(46.1±8.2) h and (42.5±11.7) h in turn,the difference was significant (P<0.05).Compared with the group before treatment,levels of serum GAS and MOT after therapy in the two groups was evidently decreased,and the value of SS was greatly increased (P<0.05).Compared with the control group after treatment, the decrease range of serum GAS and MOT,and increase range of SS after treatment in the research group was more obvious with statistical differences (P<0.05).There was no obvious adverse drug reaction in two groups. Conclusion Xingpi yanger granule as an adjuvant therapy on treating pediatric pneumonia secondary diarrhea obtains a remarkable effect by quickly alleviating diarrhea and shortening treatment time of pneumonia.Meanwhile,Xingpi yanger granule plays obvious regulating roles in the levels of GAS,MOT and SS.which is worthy of clinical promotion.
